Author Affiliation: Department of Dermatology, University of Utah, Salt Lake City, Utah.
In the article titled “Rituximab for Patients With Refractory Mucous Membrane Pemphigoid ” by Le Roux-Villet et al,1 the authors bring into focus the exceptional value of rituximab in a disease that can cause blindness and extensive mucosal scarring. Therapy for refractory patients in this study is quite remarkable and offers hope to those who have been the victim of severe morbidity and complications from the disease and from the therapy.
Zone JJ. Taking Responsibility for Complex Medical Dermatology Patient Management: Comment on “Rituximab for Patients With Refractory Mucous Membrane Pemphigoid ”. Arch Dermatol. 2011;147(7):850. doi:https://doi.org/10.1001/archdermatol.2011.166
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: